Shusuke Tsuzuki

30PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapyPharmacogenomicsSurgery
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Aug 08, 2026
Real-World Outcomes of Combination Therapy With Radium-223 and Enzalutamide Compared With Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer.

|Jun 15, 2026
Recurrence and timing of conversion to radical nephroureterectomy after endoscopic laser ablation for upper tract urothelial carcinoma: a multicenter Japanese study.

|Apr 21, 2026
Prognostic impact of large cribriform architecture and intraductal carcinoma of the prostate in diagnostic biopsies of mCSPC receiving ARPI-based therapy.

|Apr 20, 2026
Author's reply to 'Bayesian interpretation of febrile neutropenia risk and primary G-CSF prophylaxis during darolutamide triplet therapy'.

|Mar 12, 2026
Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis.

Kazuki Nishimura, Kensuke Hirosuna, Heima Niigawa

|Feb 03, 2026
Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel.

Taizo Uchimoto, Kensuke Hirosuna, Heima Niigawa

Pageof 5

Frequent Collaborators

24 joint publications

Fumihiko Urabe

19 joint publications

Takahiro Kimura

14 joint publications

Jun Miki

9 joint publications

Takafumi Yanagisawa